Dr. Reddys Laboratories Ltd.

Dr. Reddy's Laboratories is currently trading at Rs. 4322.40, up by 271.95 points or 6.71% from its previous closing of Rs. 4050.45 on the BSE.

The scrip opened at Rs. 4099.00 and has touched a high and low of Rs. 4334.20 and Rs. 4082.45 respectively. So far 118565 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4,334.20 on 29-July-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 4334.20 and Rs. 3963.85 respectively. The current market cap of the company is Rs. 71777.54 crore.

The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.97% and 15.25% respectively.

Dr. Reddy’s Laboratories has received approval of XEGLYZE (abametapir) lotion, 0.74%, a 505(b)(1) NDA by the U.S. Food and Drug Administration (USFDA). The approval triggers the contractual pre-commercialization milestone of $20 million payable to Hatchtech Pty.

XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The company is working to commercialize this product through partners.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.